Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ChAdOx1/MVA Prime-Boost HIV Vaccines in ART-Suppressed PWH
NCT05604209Phase 1Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Oct 2022
- Primary completion
- Sep 2024
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ChAdOx1.HIVconsv62, ChAdOx1.tHIVconsv1, MVA.tHIVconsv4 and MVA.tHIVconsv3 in human immunodeficiency virus infection (HIV) (3 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event at 2 months. Started Oct 2022; status: completed.
02
Drugs
ChAdOx1.HIVconsv62ChAdOx1.tHIVconsv1MVA.tHIVconsv4MVA.tHIVconsv3
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05604209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05604209.